VAMP (vinblastine, doxorubicin, methotrexate, prednisone)
Checked 2026-09-09
Favourable early-stage Hodgkin lymphoma in children and adolescents (Stanford, St Jude and Dana-Farber), with low-dose involved-field radiotherapy
Also called VAMP.
One cycle
every 28 days × 4 · about 16 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Vinblastine Vinca alkaloid (microtubule inhibitor) | 6 mg/m² | IV | D1, 15 | |
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 25 mg/m² | IV | D1, 15 | |
Methotrexate Antifolate (DHFR inhibitor) | 20 mg/m² | IV | D1, 15 | |
Prednisone Glucocorticoid | 40 mg/m² once daily | Oral | D1-14 |
Cycles
4
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Designed without alkylating agents, bleomycin or etoposide to spare fertility, lungs and second cancers in children with low-risk disease.
- A later trial tested VAMP alone without radiotherapy for early responders.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
ICE
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
every 14 days × 2-3
Escalated BEACOPP
Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles
every 21 days × 4-6
MOPP
Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD
every 28 days × 6
Stanford V
Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial
every 28 days × 3
ABVE-PC
Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy
every 21 days × 4-5